2,3-benzodiazepines (GYKI 52466 and analogs): Negative allosteric modulators of AMPA receptors

CNS Drug Reviews

Volumn 2, Issue 1, 1996, Pages 91-126

  Vizi, E S ^a   Mike, A ^a   Tarnawa, I ^b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b Institute for Drug Research Budapest   (Hungary)

Author keywords

2,3 benzodiazepines; AMPA receptor antagonists; antiepileptic drugs; glutamatergic neurotransmission; GYKI 52466; muscle tone; negative modulators; neuroprotection

Indexed keywords

1 (1,3 BENZODIOXOL 5 YL CARBONYL)PIPERIDINE; 1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 AMINOCYCLOPENTANE 1,3 DIACARBOXYLIC ACID; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7 DINITRO 2,3 QUINOXALINEDIONE; 7 CHLORO 3,4 DIHYDRO 3 METHYL 2H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANIRACETAM; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CYCLOTHIAZIDE; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DIAZEPAM; EXCITATORY AMINO ACID; GIRISOPAM; GLUTAMIC ACID; GYKI 52332; GYKI 52895; KAINIC ACID; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; QUISQUALIC ACID; TALAMPANEL; TOFISOPAM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG MECHANISM; ELECTROPHYSIOLOGY; HUMAN; MEMORY; MUSCLE TONE; NERVE CELL DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; REVIEW; SPINAL REFLEX; STRUCTURE ACTIVITY RELATION;

EID: 0029919868     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1996.tb00292.x     Document Type: Review

References (210)

1. Andine P, Jacobson I, Hagberg H. Calcium uptake evoked by electrical stimulation is enhanced post-ischemically and precedes delayed neuronal death in CA1 of rat hippocampus: Involvement of N-methyl-D-aspartate receptors. J Cereb Blood Flow Metab 1988;8:799-807.
2. Arvin B., Lekieffre D, Graham JL, Moncada C, Chapman AG, Meldrum BS. Effect of the non-NMDA receptor antagonist GYKI 52466 on the microdialysate and tissue concentrations of amino acids following transient forebrain ischaemia. J Neurochem 1994;62:1458-1467.
3. Arvin B, Moncada C, Le Peillet E, Chapman A, Meldrum BS. GYKI 52466 blocks the increase of extracellular glutamate induced by ischaemia. Neuroreport 1992;3:235-238.
4. Auer R, Kalimo H, Olsson Y, Wieloch T. The dentate gyrus in hypoglycemia: Pathology implicating excitotoxin- mediated neuronal necrosis. Acta Neuropathol (Berl) 1985;67:279-288.
5. Auer RN. Progress review: Hypoglycemic brain damage. Stroke 1986;17:699-708.
6. Bashir ZI, Bortolotto ZA, Davies CH, et al. Induction of LTP in the hippocampus needs synaptic activation of glutamate metabotropic receptors. Nature 1993;363:347-350.
7. Bensimon G, Lacomblez L, Meininger V, and ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Eng J Med 1994;330:585-591.
8. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984;43:1369-1374.
9. Bertolino M, Baraldi M, Parenti C, et al. Modulation of AMPA/kainate receptors by analogues of diazoxide and cyclothiazide in thin slices of rat hippocampus. Receptors Channels 1993;I:267-278.
10. Berzsenyi P, Tarnawa I, Farkas S, Andrasi, F. Pharmacology of a new centrally acting muscle relaxant. Pharmacol Res Commun 1988;20 Suppl1:139-140.
11. Bianchi AL, Denavit-Saubie M, Champagnat J. Central control of breathing in mammals: Neuronal circuitry, membrane properties, and neurotransmitters. Physiol Rev 1995;75:1-45.
12. Bisaga A, Krzascik P, Jankowska E, Palejko W, Kostowski W, Danysz W. Effect of glutamate antagonists on NMDA- and AMPA-induced behavioral effects in mice and rats. Eur J Pharmacol 199;242: 213-220.
13. Bliss TVP, Collingridge GL. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 1993;361:31-39.
14. Block F, Schwarz M. The depressant effect of GYKI 52466 on spinal reflex transmission in rats is mediated via non-NMDA and benzodiazepine receptors. Eur J Pharmacol 1994;256:149-153.
15. Boulter J, Hollmann M, O'Shea-Greenfield, et al. Molecular cloning and functional expression of glutamate receptor subunit genes. Science 1990;249:1033-1037.
16. Buchan AM, Lesiuk H, Barnes KA, et al. AMPA antagonists: Do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke 1993;24:1148-1152.
17. Budai D, Larson AA. GYKI 52466 inhibits AMPA/kainate and peripheral mechanical sensory activity. Neuroreport 1994;5:881-884.
18. Butcher SP, Bullock R, Graham DI, McCulloch J. Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke 1990;21:1727-1733.
19. Carlsson M, Carlsson A. Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J Neural Transm 1989;77:65-71.
20. Carlsson M, Carlsson A. Interaction between glutamatergic and monoaminergic system within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990;13:272-276.
21. Chapman AG. Excitatory amino acid antagonists and therapy of epilepsy. In: Meldrum BS, ed. Excitatory amino acid antagonists. London: Blackwell Scientific Publications, 1991;265-286.
22. Chapman AG, al-Zubaidy Z, Meldrum BS. Aniracetam reverses the anticonvulsant action of NBQX and GYKI 52466 in DBA/2 mice. Eur J Pharmacol 1993;231:301-303.
23. Chapman AG, Smith SE, Meldrum BS. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res 1991;9:92-96.
24. Chen K, Hernandez YM, Dretchen KL, Gillis RA. Intravenous NBQX inhibits spontaneously occurring sympathetic nerve activity and reduces blood pressure in cats. Eur J Pharmacol 1994;252:155-160.
25. Chenard BL, Butler TW, Menniti FS, Prochniak MA, Richter KEG. A short synthesis of GYKI 52466. Bioorg Med Chem Lett 1993;3:1991-1992.
26. Chizh BA, Cumberbatch MJ, Headley PM. A comparison of intravenous NBQX and GYKI 53655 as AMPA antagonists in the rat spinal cord. Br J Pharmacol 1994; 112:843-846.
27. Choi DW. Ionic dependence of glutamate neurotoxicity. J Neurosci 1987;7:369-379.
28. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-634.
29. Choi DW, Maulucci-Gedde M, Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. J Neurosci 1987;7:357-368.
30. Churn SB, Sombati S, Taft WC, DeLorenzo RJ. Excitotoxicity affects membrane potential and calmodulin kinase II activity in cultured rat cortical neurons. Stroke 1993;24:271.
31. Clifford DB, Zorumski CF, Olney JW. Ketamine and MK-801 prevent degeneration of thalamic neurons induced by focal cortical seizures. Exp Neurol 1989;105:272-279.
32. Collingridge GL, Singer W. Excitatory amino acid receptors and synaptic plasticity. Trends Neurosci 1990;11:290-296.
33. Collins RC, Olney JW. Focal cortical seizures cause distant thalamic lesions. Science 1982;218:177-179.
34. Cumberbatch MJ, Chizh BA, Headley PM. AMPA receptors have an equal role in spinal nociceptive and non-nociceptive transmission. Neuroreport 1994;5:877-880.
35. 2+ channel agonist. Bay K 8644, on the anticonvulsant activity of NMDA and non-NMDA receptor antagonists. Eur J Pharmacol 1994;264:103-106.
36. Danysz W, Essmann U, Bresink I, Wilke R. Glutamate antagonists have different effects on spontaneous Iocomotor activity in rats. Pharmacol Biochem Behav 1994;48:111-118.
37. Davies J, Watkins JC. Role of excitatory amino acid receptors in mono- and polysynaptic excitation in the cat spinal cord. Exp Brain Res 1983;49:280-290.
38. 2+], homeostasis in cultures of embryonic dopaminergic neurons. Brain Res Mol Brain Res 1994;21:303-311.
39. 2+ channels. Neurosci Lett 1992;145:121-125.
40. de Erasquin GA, Costa E, Hanbauer I. Calcium homeostasis, free radical formation, and trophic factor dependence mechanisms in Parkinson's disease. Pharmacol Rev 1994;46:467-482.
41. Desai MA, Burnett JP, Ornstein PL, Schoepp DD. Cyclothiazide acts at a site on the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor complex that does not recognize competitive or noncompetitive AMPA receptor antagonists. J Pharmacol Exp Ther 1995;272:38-43.
42. 3H]norepinephrine release in rat hippocampal slices. Neuropharmacology 1995;34:141-147.
43. Di Fazio MC, Hollingsworth Z, Young AB, Penney JB, Jr. Glutamate receptors in the substantia nigra of Parkinson's disease brains. Neurology 1992;42:402-406.
44. Donevan SD, Rogawski MA. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 1993;10:51-59.
45. Donevan SD, Yamaguchi S, Rogawski MA. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: Relationship to anticonvulsant activity. J. Pharmacol Exp Ther 1994;271:25-29.
46. Durmuller N, Craggs M, Meldrum BS. The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res 1994;17:167-174.
47. Eastwood SL, McDonald B, Burnet PWJ, Beckwith JP, Karwin RW, Harrison PJ. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res Mol Brain Res 1995;29:211-223.
48. 2+ permeability of unedited and edited versions of the kainate selective glutamate receptor GluR6. Proc Natl Acad Sci USA 1993;90:755-759.
49. Engberg I, Tarnawa I, Durand J, Ouardouz M. An analysis of synaptic transmission to motoneurones in the cat spinal cord using a new selective receptor blocker. Acta Physiol Scand 1993;148:97-100.
50. Evans RH. The pharmacology of segmental transmission in the spinal cord. Prog Neurobiol 1989;33: 255-279.
51. Faden Al, Demediuk P, Panter SS, Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989;244:798-800.
52. Faden Al, Ellison JA, Noble LJ. Effects of competitive and non-competitive NMDA receptor antagonists in spinal cord injury. Eur J Pharmacol 1990;175:165-174.
53. Farkas S, Ono H. Participation of NMDA and non-NMDA excitatory amino acid receptors in the mediation of spinal reflex potentials in rats; An in vivo study. Br J Pharmacol 1995;114:1193-1205.
54. Farkas S, Tarnawa I, Berzsenyi P. Effects of some centrally acting muscle relaxants on spinal root potentials: A comparative study. Neuropharmacology 1989;28:161-173.
55. Farkas S, Tarnawa I, Berzsenyi P, Patfalusi M, Andrasi F, Ono H. The role of non-NMDA excitatory amino acid receptors in the mediation of spinal reflexes. In: Frontiers and new horizons in amino acid research. Takai, R, ed. Amsterdam:Elsevier, 1992:471-475.
56. Flatman, J.A., Durand, J., Engberg, I., and Lambert, J.D.C. Blocking the monosynaptic EPSP in spinal cord motoneurones with inhibitors of amino acid excitation. In: Hicks TP, et al, eds. Excitatory Amino Acid Transmission. New York: Alan R. Liss, 1987:285-292.
57. 2+ calmodulin-dependent protein kinase II and protein kinase C by glutamate in cultured rat hippocampal neurons. J Biol Chem 1992;267:22527-22533.
58. Garthwaite G, Garthwaite J. Neurotoxicity of excitatory amino acid receptor agonists in rat cerebellar slices: Dependence on calcium concentration. Neurosci Lett 1986;66:193-198.
59. Gill R. The pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate (AMPA)/kainate antagonists and their role in cerebral ischaemia. Cerebrovasc Brain Metab Rev 1994;6:225-256.
60. Goldberg HL, Finnerty RJ. Comparative efficacy of tofisopam and placebo. Am J Psychiatry 1979;136: 196-199.
61. Graham SH, Shiraishi K, Panter SS, Simon RP, Faden A. Changes in extracellular amino acid neurotransmitters produced by focal cerebral ischemia. Neurosci Lett 1990;110:124-130.
62. Greenamyre JT, O'Brien CF. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 1991;48:977-981.
63. Haefely W, Pierry L, Pole P, Schaffner R. General pharmacology and neuropharmacology of benzodiazepine derivatives. In: Handbook of Experimental Pharmacology. Hoffmeister F, Stille G, eds. Berlin, Heidelberg, New York: Springer-Verlag, 1981:13-262.
64. Hagberg H, Lehmann A, Sandberg M, Nystrom B, Jacobson I, Hamberger A. Ischemia-induced shift of inhibitory and excitatory amino acids from intra- to extracellular compartments. J Cereb Blood Flow Metab 1985;5:413-419.
65. Hauber W, Andersen R. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn-Schmiedebergs Arch Pharmacol 1993;348:486-490.
66. Hauber W, Waldenmeier MT. The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849. Eur J Pharmacol 1994;256:339-342.
67. Hillered L, Hallstrom A, Segersvard S, Persson L, Ungerstedt U. Dynamics of extracellular metabolites in the striatum after middle cerebral artery occlusion in the rat monitored by intracerebral microdialysis. J Cereb Blood Flow Metab 1989;9:607-616.
68. 2+ permeability of KA-AMPA gated glutamate receptor channels depends on subunit composition. Science 1991;252:851-853.
69. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994;17:31-108.
70. Honore T, Davies SN, Drejer J, et al. Quinoxalinediones: Potent competitive non-NMDA glutamate receptor antagonists. Science 1988;241:701-703.
71. Horvath EJ, Palkovits M, Lenkei Z, Gyire KI, Fekete MIK, Aranyi P. A novel specific binding site for homophthalazines in the rat brain. Eur J Pharmacol 1993;236:151-153.
72. Horvath K, Szabo H, Patfalusi M, Berzsenyi P, Andrasi F. Pharmacological effects of GYKI 52895, a new selective dopamine uptake inhibitor. Eur J Pharmacol 1990;183:1416-1417.
73. Horváth K, Andrási F, Berzsenyi P, et al. A new psychoactive 5H-2,3-benzodiazepine with a unique spectrum of activity. Arzneimittelforschung 1989;39:894-899.
74. 2+ in cultured neurones from rat brain. J Neurochem 1995;64:2049-2056.
75. Hume RI, Dingledine R, Heinemann SF. Identification of a site in glutamate receptor subunits that controls calcium permeability. Science 1991;253:1028-1031.
76. Hylton C, Perri B, Voddi M, et al. Non-NMDA antagonist GYKI 52466 enhances spatial memory after experimental brain injury. J Neurotrauma 1995;12:124.
77. lino M, Ozawa S, Tsuzuki K. Permeation of calcium through excitatory amino acid receptor channels in cultured rat hippocampal neurones. J Physiol (Lond) 1990;424:151-165.
78. Ikeda M, Nakazawa T, Abe K, Kaneko T, Yamatsu K. Extracellular accumulation of glutamate in the hippocampus induced by ischemia is not calcium dependent - in vitro and in vivo evidence. Neurosci Lett 1989;96:202-206.
79. Jahr CE, Yoshioka K. Ia afferent excitation of motoneurones in the in vitro newborn rat spinal cord is antagonized by kynurenate. J Physiol (Lond) 1986;370:515-530.
80. Kameyama T, Nabeshima T, Sugimoto A, Matsumo K, Yamada S. Antinociceptive action of tizanidine in mice and rats. Naunyn-Schmiedebergs Arch Pharmacol 1985;330:93-96.
81. Keinanen K, Wisden W, Sommer B, et al. A family of AMPA-selective glutamate receptors. Science 1990;249:556-560.
82. Kiss JP, Toth E, Lajtha A, Vizi ES. NMDA receptors are not involved in the MK-801-induced increase of striatal dopamine release in rat: A microdialysis study. Brain Res 1994;641:145-148.
83. Klockgether T, Turski L. Excitatory amino acids and the basal ganglia: Implications for the therapy of Parkinson's disease. Trends Neurosci 1989;12:285-286.
84. Klockgether T, Turski L, Honore T, et al. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 1991;30:717-723.
85. Koh JY, Choi DW. Selective blockade of non-NMDA receptors does not block rapidly triggered glutamate-induced neuronal death. Brain Res 1991;548:318-321.
86. Kubo T, Amano M, Asari T. N-methyl-D-aspartate receptors but not non-N-methyl-D-aspartate receptors mediate hypertension induced by carotid body chemoreceptor stimulation in the rostral ventrolateral medulla of the rat. Neurosci Lett 1993;164:113-116.
87. Le Peillet E, Arvin B, Moncada C, Meldrum BS. The non-NMDA antagonists NBQX and GYKI 52466 protect against cortical and striatal cell loss following transient global ischaemia in the rat. Brain Res 1992;571:115-120.
88. Leander JD. Behavioral pharmacology of non-competitive AMPA receptor antagonists. Proc Behav Pharmacol Soc, 1994, Cambridge, USA.
89. Lees GJ. Contributory mechanisms in the causation of neurodegenerative disorders. Neuroscience 1993;54:287-322.
90. Lees GJ, Leong W. Differential effects of NBQX on the distal and local toxicity of glutamate agonists administered intra-hippocampally. Brain Res 1993;628:1-7.
91. Lerma J, Paternain AV, Naranjo JR, Mellstrom B. Functional kainate-selective glutamate receptors in cultured hippocampal neurons. Proc Natl Acad Sci USA 1993;90:11688-11692.
92. Li F, Verdoorn TA. Structural correlates of agonist binding to recombinant AMPA receptors. Soc Neurosci Abs 1994;20:211.1.
93. Li H, Buchan AM. Treatment with an AMPA antagonist 12 hours following severe normothermic forebrain ischemia prevents CA1 neuronal injury. J Cereb Blood Flow Metab 1993;13:933-939.
94. + currents in hippocampal neurons. Soc Neurosci Abs 1994;20:630.13.
95. Ling I, Podolanyi B, Hamori T, Solyom S. Asymmetric reduction of carbon-nitrogen double bond: Enantioselective synthesis of 3,4-dihydro-5H-2,3-benzodiazepines. J Chem Soc PerkinTrans 1 1995;1423-1427.
96. Lippert K, Welsch M, Krieglstein J. Over-additive protective effect of dizocilpine and NBQX against neuronal damage. Eur J Pharmacol 1994;253:207-213.
97. Lipton P, Lobner D. Mechanisms of intracellular calcium accumulation in the CA1 region of rat hippocampus during anoxia in vitro. Stroke 1990;21(11 Suppl):11160-11164.
98. Lobner D, Lipton P. Sigma-ligands and non-competitive NMDA antagonists inhibit glutamate release during cerebral ischemia. Neurosci Lett 1990;117:169-174.
99. Lodge D. Excitatory Amino Acids in Health and Disease. New York: John Wiley & Sons Ltd, 1988.
100. Lodge D, Bond A, Palmer AJ. Stereospecific effects of 2,3-benzodiazepine as antagonists of alpha-amino-3-hydroxy-5-methyl-isoxazolepropionate (AMPA). Br J Pharmacol 1994;112:13P.
101. Lodge D, Jones MG, Palmer AJ, Zeman S. Electrophysiology of glutamate receptors. In: Schousboe A, et al, eds. Drug Research Related to Neuroactive Amino Acids. Copenhagen: Munksgaard, 1992: 153-160.
102. Lombardi G, Moroni F. Glutamate receptor antagonists protect against ischemia-induced retinal damage. Eur J Pharmacol 1994;271:489-495.
103. Long SK, Smith DAS, Siarey RJ, Evans RH. Effect of 6-cyano-2,3-dihydroxy-7-nitro-quinoxaline (CNQX) on dorsal root-, NMDA-, kainate- and quisqualate-mediated depolarization of rat motoneurones in vitro. Br J Pharmacol 1990;100:850-854.
104. Loscher W, Honack D. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: Comparison with diazepam and interactions with flumazenil. Br J Pharmacol 1994;113:1349-1357.
105. Loscher W, Rundfeldt C, Honack D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur J Neurosci 1993;5:1545-1550.
106. Loschmann PA, Kunow M, Wachtel H. Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease. J Neural Transm Suppl. 1992;38:55-64.
107. MacDermott AB, Mayer ML, Westbrook GL, Smith SJ, Barker JL. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones [published erratum appears in Nature 321:888]. Nature 1986;321:519-522.
108. Marcoux FW. Pharmacologic therapeutic window in acute stroke. Drug News and Perspectives 1994;7:228-235.
109. Martin LJ, Blackstone CD, Levey AI, Huganir RL, Price DL. AMPA glutamate receptor subunits are differentially distributed in rat brain. Neuroscience 1993;53:327-358.
110. May PC, Robinson PM. GYKI 52466 protects against non-NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures. Neurosci Lett 1993;152:179-184.
111. Mayer ML, Westbrook GL. The physiology of excitatory amino acids in the vertebrate central nervous system. Prog Neurobiol 1987;28:197-276.
112. McCulloch J, Bullock R, Teasdale GM. Excitatory amino acid antagonists: Opportunities for the treatment of ischaemic brain damage in man. In: Meldrum, BS ed. Excitatory Amino Acid Antagonists. London: Blackwell, 1991;287-326.
113. McDonald JW, Fix AS, Tizzano JP, Schoepp DD. Seizures and brain injury in neonatal rats induced by 1S,3R-ACPD, a metabotropic glutamate receptor agonist. J Neurosci 1993;13:4445-4455.
114. McGlade-McCulloh E, Yamamoto H, Tan SE, Brickey DA, Soderling TR. Phosphorylation and regulation of glutamate receptors by calcium/calmodulin-dependent protein kinase II. Nature 1993;362: 640-642.
115. Meldrum BS, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990;11:379-387.
116. Meldrum BS. Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters. Clinical Science 1985;68:113-122.
117. Meldrum BS, Craggs MD, Durmuller N, Smith SE, Chapman AG. The effects of AMPA receptor antagonists on kindled seizures and on reflex epilepsy in rodents and primates. Epilepsy Res Suppl 1992;9:307-311.
118. Miller RJ. The revenge of the kainate receptor. Trends Neurosci 1991;14:477-479.
119. Milusheva E, Doda M, Pasztor E, Lajtha A, Sershen H, Vizi ES. Regulatory interactions among axon terminals affecting the release of different transmitters from rat striatal slices under hypoxic and hypoglycemic conditions. J Neurochem 1992;59:946-952.
120. 3H]dopamine in rat striatal slices. Neurochemistry International 1995 (in press).
121. Moncada C, Arvin B, Le Peillet E, Meldrum BS. Non-NMDA antagonists protect against kainate more than AMPA toxicity in the rat hippocampus. Neurosci Lett 1991;133:287-290.
122. Monn JA, Schoepp DD. Recent progress in excitatory amino acid research. Ann Rep Med Chem 1994;29:53-64.
123. Muller D, Joly M, Lynch G. Contributions of quisqualate and NMDA receptors in the induction and expression of LTP. Science 1989;242:1694-1697.
124. ++ influx into striatal neurons by kainic acid. J Pharmacol Exp Ther 1989;249:184-193.
125. Nakanishi S. Metabotropic glutamate receptors: Synaptic transmission, modulation, and plasticity. Neuron 1994;13:1031-1037.
126. 123a. Nicoletti F, Wroblewski JT, Novelli A, Alho H, Guidotti A, Costa E. The activation of inositol phospholipid metabolism as a signal-transducing system for excitatory amino acids in primary cultures of cerebellar granule cells. J Neurosci 1986;6:1905-1911.
127. Nicotera P, Bellomo G, Orrenius S. Calcium-mediated mechanisms in chemically induced cell death. Annu Rev Pharmacol Toxicol 1992;32:449-470.
128. Nooney JM, Feltz A. Inhibition by cyclothiazide of neuronal nieotinic responses in bovine chromaffin cells. Br J Pharmacol. 1995;114:648-655.
129. Olney JW. Glutamate, a neurotoxic transmitter. J Child Neurol 1989;4:218-226.
130. Olney JW, deGubareff T, Sloviter RS. "Epileptic" brain damage in rats induced by sustained electrical stimulation of the perforant path. II. Ultrastructural analysis of acute hippocampal pathology. Brain Res Bull 1983;10:699-712.
131. Olney JW, Price MT, Labruyere J, et al. Anti-parkinsonian agents are phencyclidine agonists and N-methyl aspartate antagonists. Eur J Pharmacol 1987;142:319-320.
132. 128a. Olney JW, Zorumski CF, Stewart GR, Price MT, Wang G, Labruyere J. Excitotoxicity of L-DOPA and 6-OH-DOPA: Implications for Parkinson's and Huntington's disease's. Exp Neurol 1990;108:269-272.
133. Osipenko O, Mike A, Gyevai A, Vizi ES. Evidence that GYKI 52466, a novel non-NMDA antagonist enhances the decay of kainate-induced current in cultured chicken cortical neurons. Brain Res Dev Brain Res 1994;77:257-263.
134. Ouardouz M, Durand J. GYKI 52466 antagonizes glutamate responses but not NMDA and kainate responses in rat abducens motoneurones. Neurosci Lett 1991;125:5-8.
135. Ouardouz M, Durand J. Involvement of AMPA receptors in trigeminal postsynaptic potentials recorded in rat abducens motoneurons in vivo. Eur J Neurosci 1994;6:1662-1668.
136. Palmer AJ, Lodge D. Cyclothiazide reverses AMPA receptor antagonism of the 2,3-benzodiazepine, GYKI 53655. Eur J Pharmacol 1993;244:193-194.
137. Parsons CG, Gruner R, Rozental J. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) and 1-(4-amino-phenyl)-4-methyl-7,8-methylendioxyl-5H-2,3-benzodiazepine (GYKI 52466). Neuropharmacology 1994;33:589-604.
138. Partin KM, Patneau DK, Mayer ML. Splice variants of AMPA receptors are differentially modulated by cyclothiazide. Soc Neurosci Abs 1994;211.5.
139. Paternain AV, Morales M, Lerma J. Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron 1995;14:185-189.
140. Patneau DK, Vyklicky LJr, Mayer ML. Hippocampal neurons exhibit cyclothiazide-sensitive rapidly desensitizing responses to kainate. J Neurosci 1993;13:3496-3509.
141. Pearce PC, Maclean CJ, Shergill HK, et al. Protection from high pressure induced hyperexcitability by the AMPA/kainate receptor antagonists GYKI 52466 and LY 293558. Neuropharmacology 1994;33:605-612.
142. Pellegrini-Giampietro DE, Zukin RS, Bennett MV, Cho S, Pulsinelli WA. Switch in glutamate receptor subunit gene expression in CA1 subfield of hippocampus following global ischemia in rats. Proc Natl Acad Sci USA 1992;89:10499-10503.
143. Phillis JW, Smith-Barbour M, Perkins LM, O'Regan MH. GYKI 52466 and ischemia-evoked neurotransmitter amino acid release from rat cerebral cortex. Neuroreport 1993;4:109-111.
144. Piercey MF, Hollister RP. Effects of intravenous baclofen on dorsal horn neurons of spinal cats. Eur J Pharmacol 1979;53:379-382.
145. Pierrefiche O, Foutz AS, Champagnat J, Denavit-Saubie M. NMDA and non-NMDA receptors may play distinct roles in timing mechanisms and transmission in the feline respiratory network. J Physiol (Lond) 1994;474:509-523.
146. Prehn JHM, Lippert K, Krieglstein J. Are NMDA or AMPA/kainate receptor antagonists more efficacious in the delayed treatment of excitotoxic neuronal injury. Eur J Pharmacol 1995;292:179-189.
147. Rammes G, Muller W, Swandulla D, Parsons CG, Collingridge GL. Interactions of GYKI 52466 and cyclothiazide: Patch clamp studies. Soc Neurosci Abs 1994;20:630.2.
148. Rammes G, Parsons C, Muller W, Swandulla D. Modulation of fast excitatory synaptic transmission by cyclothiazide and GYKI 52466 in the rat hippocampus. Neurosci Lett 1994;175:21-24.
149. Rees H, Sluka KA, Westlund KN, Willis WD. Do dorsal root reflexes augment peripheral inflammation? NeuroReport 1994;5:821-824.
150. 145a. Renard A, Crepel F, Audinat E. Evidence for two types of non-NMDA receptors in rat cerebellar Purkinje cells maintained in slice cultures. Neuropharmacology 1995;335-346.
151. Richter A, Loscher W, Loschmann PA. The AMPA receptor antagonist NBQX exerts antidystonic effects in an animal model of idiopathic dystonia. Eur J Pharmacol 1993;231:287-291.
152. Rockett IR, Smith GS. Injuries in relation to chronic disease: An international view of premature mortality. Am J Public Health 1987;77:1345-1346.
153. Rogawski MA. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 1993;14:325-331.
154. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
155. Rothstein JD, Bristol LA, Hosler B, Brown RH Jr, Kuncl RW Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci USA 1994;91:4155-4159.
156. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993;90:6889-6893.
157. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Eng J Med 1992;326:1464-1468.
158. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25.
159. Salamon C, Horvath EJ, Fekete MI, Aranyi P. A novel specific binding site for anxiolytic homophthalazines in the rat brain. FEBS Lett 1992;308:215-217.
160. Sandberg M, Butcher SP, Hagberg H. Extracellular overflow of neuroactive amino acids during severe insulin- induced hypoglycemia: In vivo dialysis of the rat hippocampus. J Neurochem 1986;47:178-184.
161. Sauer D. EAA receptors and excitotoxicity. Drug News and Perspectives 1993;6:88-94.
162. Schmidt WJ, Bubser M. Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav. 1989;32:621-623.
163. Scott CW, Caputo CB. New avenues for therapeutic intervention in Alzheimer's disease. Drug News and Perspectives 1994;7:269-278.
164. Seeburg PH. The TINS/TIPS Lecture. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci 1993;16:359-365.
165. Sharp RL, May PC, Mayne NG, Snyder YM, Burnett JP. Cyclothiazide potentiates agonist responses at human AMPA/kainate receptors expressed in oocytes. Eur J Pharmacol 1994;266:R1-R2.
166. Sharp RL, Mayne NG, Burnett JP. Cyclothiazide differentially modulates human metabotropic glutamate receptors linked to phosphoinositide hydrolysis stimulation in oocytes. Eur J Pharmacol Molec Pharm Sect 1994;269:R5-R7.
167. Sheardown MJ. The triggering of spreading depression in the chicken retina: A pharmacological study. Brain Res 1993;607:189-194.
168. Sheardown MJ, Nielsen EO, Hansen AJ, Jacobsen P, Honore T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxa!ine: A neuroprotectant for cerebral ischemia. Science 1990;247:571-574.
169. Siman R, Noszek JC, Kegerise C. Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J Neurosci 1989;9:1579-1590.
170. Sluka KA, Westlund KN. Centrally administered non-NMDA but not NMDA receptor antagonists block peripheral knee joint inflammation. Pain 1993;55:217-225.
171. Smith ML, Auer RN, Siesjö BK. The density and distribution of ischemic brain injury in the rat following 2-10 min of forebrain ischemia. Acta Neuropathol (Berl) 1984;64:319-332.
172. Smith SE, Durmuller N, Meldrum BS. The non-N-methyl-D-aspartate receptor antagonists GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur J Pharmacol 1991;201:179-183.
173. Smith SE, Meldrum BS. Receptor site specificity for the acute effects of beta-N-methylamino-alanine in mice. Eur J Pharmacol 1990;187:131-134.
174. Smith SE, Meldrum BS. Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischaemia in the rat. Stroke 1992;23:861-864.
175. Song X-J, Zhao Z-Q. Differential effect of NMDA and non-NMDA receptor antagonists an spinal cutaneous vs. muscular nociception in the cat. Neuroreport 1993;4:17-20.
176. Sonsalla PK, Niklias WJ, Heikkila RE. Role for excitatory amino acids in metamphetamine-induced nigrostriatal dopaminergic toxicity. Science 1989;243:398-400.
177. Staubli U, Ambros-Ingerson J, Lynch G. Receptor changes and LTP: An analysis using aniracetam, a drug that reversibly modifies glutamate (AMPA) receptors. Hippocampus 1992;2:49-57.
178. Staubli U, Rogers G, Lynch G. Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA 1994;91:777-781.
179. Steppuhn KG, Turski L. Diazepam dependence prevented by glutamate antagonists. Proc Natl Acad Sci USA 1993;90:6889-6893.
180. Sugiyama H, Ito I, Hirono C. A new type of glutamate receptor linked to inositol phospholipid metabolism. Nature 1987;325:531-533.
181. 3H]GYKI 53405 to Xenopus brain membranes. Neuroreport 1993;5:93-94.
182. Szatkowski M, Attwell D. Triggering and execution of neuronal death in brain ischaemia: Two phases of glutamate release by different mechanisms. Trends Neurosci 1994;17:359-365.
183. Tarnawa I, Berzsenyi P, Andrasi F, et al. Structure-activity relationships among 2,3-benzodiazepine compounds with AMPA antagonistic action. Bioorg Med Chem Lett 1993;3:99-104.
184. Tarnawa I, Engberg I, Flatman JA. GYKI 52466 an inhibitor of spinal reflexes is a potent quisqualate antagonist. In: Lubec G, Rosenthal GA eds. Amino Acids: Chemistry, Biology and Medicine. Leiden: Escom Science Publishers B.V. 1990;538-546.
185. Tarnawa I, Farkas S. In vivo and in vitro electrophysiological actions of novel 2,3-benzodiazepine AMPA antagonists. Br J Pharmacol 1994;112:11P.
186. Tarnawa I, Farkas S, Berzsenyi P, Pataki A, Andrasi F. Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant GYKI 52466. Eur J Pharmacol 1989;167:193-199.
187. Tarnawa I, Farkas S, Berzsenyi P, Patfalusi M, Andrasi F. Reflex inhibitory action of a non-NMDA type excitatory amino acid antagonist, GYKI
188. Tarnawa I, Kapus G, Banczerowski-Pelyhe I, Vilagi I. LTP induction during the blockade of AMPA receptor mediated transmission in the CA1 region of hippocampal slices. Eur J Neurosci (Suppl) 1994;7:47.09.
189. Tarnawa I, Molnar P, Gaal L, Andrasi F. Inhibition of hippocampal field potentials by GYKI 52466 in vitro and in vivo. Acta Physiol Hung 1992;79:163-169.
190. Tizzano JP, Griffey KI, Johnson JA, Fix AS, Helton DR, Schoepp DD. Intracerebral 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) produces limbic seizures that are not blocked by ionotropic glutamate receptor antagonists. Neurosci Lett 1993;162:12-16.
191. 2+ administered up to twenty-four hours following reperfusion prevents ischemic damage of the CA1 neurons in the rat hippocampus. Neuroscience 1991;44:335-339.
192. Turski L, Bressler K, Klockgether T, Stephens DN. Differential effects of the excitatory amino acid antagonists, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 3-[(±)-2-carboxypiperazin-4-yl]-propyl-1-phosphonic acid (CPP), on spinal reflex activity in mice. Neurosci Lett 1990;113:66-71.
193. Turski L, Jacobsen P, Honore T, Stephens DN. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. J Pharmacol Exp Ther 1992;260:742-747.
194. Upton N. Mechanisms of action of new antiepileptic drugs: Rational design and serendipitous findings. Trends Pharmacol Sci 1994;15:456-463.
195. Urban L, Thompson SWN, Dray A. Modulation of spinal excitability: Cooperation between neurokinin and excitatory amino acid neurotransmitters. Trends Neurosci 1994;17:432-438.
196. Valentino K, Newcomb R, Gadbois T, et al. A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc Natl Acad Sci USA 1993;90:7894-7897.
197. Verdoorn TA, Burnashev N, Monyer H, Seeburg PH, Sakmann B. Structural determinants of ion flow through recombinant glutamate receptor channels. Science 1991;252:1715-1718.
198. Vyklicky L, Jr, Patneau DK, Mayer ML. Modulation of excitatory synaptic transmission by drugs that reduce desensitization at AMPA/kainate receptors. Neuron 1991;7:971-984.
199. Walmsley B Bolton PS. An in vivo pharmacological study of single group 1a fibre contacts with motoneurones in the cat spinal cord. J Physiol (Lond) 1994;481:731-741.
200. Watkins JC, Collingridge GL. The NMDA receptor. Oxford: IRL Press, 1989.
201. Wieloch T, Engelsen B, Westerberg E, Auer R. Lesions of the glutamatergic cortico-striatal projections in the rat ameliorate hypoglycemic brain damage in the striatum. Neurosci Lett 1985;58:25-30.
202. Wrathall JR, Bouzoukis J, Choiniere D. Effect of kynurenate on functional deficits resulting from traumatic spinal cord injury. Eur J Pharmacol 1992;218:273-281.
203. Xue D, Huang ZG, Barnes K, Lesiuk HJ, Smith KE, Buchan AM. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J Cereb Flow Metab 1994;14:251-261.
204. Yamada KA, Turetsky D. Cyclothiazide and GYKI 52466 do not competitively interact on recombinant G;uR6 receptors. Soc Neurosci Abs 1994;20:108.2.
205. Yamaguchi S, Donevan SD, Rogawski MA. Anticonvulsant activity of AMPA/kainate antagonists: Comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res 15:1993, 179-184.
206. Zadow B, Schmidt WJ. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy. Naunyn-Schmiedebergs Arch Pharmacol 1994;349:61-65.
207. Zarnowski T, Kleinrok Z, Turski WA, Czuczwar SJ. 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline enhances the protective activity of common antiepileptic drugs against maximal electroshock-induced seizures in mice. Neuropharmacology 1993;32:895-900.
208. Zivkovic I, Thompson DM, Bertolino M, et al. 7-chloro-3-methyl-3,4-dihydro-2H-1,4,2-benzothiadiazine-S,S-dioxide (IDRA 21): A benzothiadiazine derivative that enhances cognition by attenuating DL-α-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J Pharm Exp Ther 1995;272:300-309.
209. Zorumski CF, Olney JW. Excitotoxic neuronal damage and neuropsychiatric disorders. Pharmac Ther 1993;59:145-162.
210. Zorumski CF, Yamada KA, Price MT, Olney JW. A benzodiazepine recognition site associated with the non-NMDA glutamate receptor. Neuron 1993;10:61-67.